Collaborations

Companies ink agreement to develop MicroPyramid-based vaccine delivery

Published in Vaccine Weekly, March 3rd, 2004

NanoPass Technologies, Ltd., has signed an agreement with GlaxoSmithKline's Biopharmaceutical Centre of Excellence for Drug Discovery (GSK) to develop NanoPass' MicroPyramid technology for the delivery of vaccines.

The aim of the collaboration is to optimize the MicroPyramid platform for vaccine delivery. The MicroPyramid technology offers the possibility to effectively and painlessly administer vaccines intra-epidermally. Conventional needles are too large to do this, and transdermal patch or chemical technologies are incapable of efficiently delivering large molecules.

According to NanoPass founder Shuki Yeshurun, "There is potential that this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-03-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry